Tirzepatide is the active ingredient behind some of the most effective weight-loss results in any clinical trial — a once-weekly dual GIP/GLP-1 injection, FDA-approved for chronic weight management as Zepbound®. Prescribed online by licensed physicians and shipped to your door.
Once-weekly injectable · FDA-approved for weight management
Tirzepatide is a once-weekly injectable medication and the first of its kind: a single molecule that activates both the GIP and GLP-1 receptors — two natural incretin hormones involved in appetite, fullness, and blood sugar. By working on two pathways instead of one, tirzepatide has produced some of the largest average weight reductions of any medication studied for obesity.
Tirzepatide is the active ingredient in two FDA-approved brand medications from Eli Lilly: Zepbound®, approved for chronic weight management, and Mounjaro®, approved for type 2 diabetes. A licensed physician determines whether tirzepatide is appropriate for you and which formulation to prescribe.
Most GLP-1 medications act on a single hormone. Tirzepatide is first-in-class because it activates two — GIP and GLP-1 — for a combined effect on appetite and metabolism.
Tirzepatide activates both GIP and GLP-1 receptors — the first medication to do so — which is linked to its strong appetite and weight effects.
Both hormones act on appetite centers in the brain, so you feel less hungry and more satisfied with smaller portions.
By slowing how quickly the stomach empties, it helps you stay full longer after meals and reduces snacking.
It improves the body's insulin response in a glucose-dependent way, which also helps curb cravings.
Among GLP-1 medications, tirzepatide stands out for its dual mechanism and for its performance in head-to-head weight-loss trials.
Tirzepatide is the first and only single-molecule medication to activate both the GIP and GLP-1 receptors — a mechanism no other approved GLP-1 shares.
In trials, tirzepatide produced average weight reductions of around 21% at the highest dose — among the largest seen for any obesity medication.
A single weekly injection makes tirzepatide easy to fit into your routine, with a gradual dose schedule to ease your body in.
Tirzepatide is the active ingredient in two FDA-approved brand medications — Zepbound® (weight management) and Mounjaro® (type 2 diabetes). Compounded tirzepatide is not FDA-approved and, following the resolution of the tirzepatide shortage, may be prescribed only in specific, patient-specific circumstances under applicable law. Your licensed physician determines the safe, appropriate, and legal option for you.
Tirzepatide starts low and increases about every four weeks so your body can adjust and side effects stay manageable. It's a once-weekly injection at every step.
The 2.5 mg starting dose helps your body adjust and isn't a maintenance dose. Your physician steps you up by 2.5 mg increments no sooner than every 4 weeks, based on your goals and tolerance — many people do well below the maximum. The maximum dose is 15 mg once weekly. Always follow your prescriber's instructions.
Tirzepatide was studied for weight management in the SURMOUNT program. These are the headline results — individual outcomes vary.
In the 72-week SURMOUNT-1 trial, adults without diabetes taking the highest dose lost an average of roughly 21% of their body weight, combined with a reduced-calorie diet and increased physical activity — among the largest reductions reported for any obesity medication.
In a direct comparison trial, tirzepatide produced about 47% greater relative weight loss than semaglutide at 72 weeks, with far more participants reaching the highest weight-loss thresholds.
* Based on the SURMOUNT clinical program. Tirzepatide is FDA-approved for chronic weight management under the brand name Zepbound®. Results combine medication with diet and exercise; individual results vary based on dose, adherence, and health history.
The two leading GLP-1 molecules for weight loss, compared. Tirzepatide adds a second hormone target, which is linked to its greater average weight loss.
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Drug class | GIP + GLP-1 dual agonist | GLP-1 receptor agonist |
| Brand medications | Zepbound® · Mounjaro® | Wegovy® · Ozempic® · Rybelsus® |
| Administration | Once-weekly injection | Weekly injection or daily pill |
| FDA-approved for weight loss | Yes (as Zepbound®) | Yes (as Wegovy®) |
| Avg. weight loss (highest dose) | ~21% | ~15% |
| Head-to-head (SURMOUNT-5) | 20.2% | 13.7% |
| Brand maker | Eli Lilly | Novo Nordisk |
Average weight-loss figures are based on pivotal clinical trials and differ by dose and population. Your physician will recommend the most appropriate option for you.
Our care team helps you find the most affordable, appropriate path — whether through insurance or a transparent cash-pay program.
A prescription is only part of the picture. Your program wraps the medication in ongoing clinical care and support to help you succeed.
If you qualify, your physician prescribes tirzepatide at the dose and formulation that fits you.
Secure telemedicine evaluations and follow-ups with licensed providers — no waiting rooms.
Guidance on titration and managing common side effects, with a team you can message.
Coordinators check coverage, apply savings programs, and lay out cash-pay options.
Track weight, doses, and milestones so you and your provider can see what's working.
Medication ships from a licensed pharmacy directly to your door, refilled on schedule.
Our telemedicine process is fast, private, and designed to take you from consultation to prescription as smoothly as possible.
Tell us about your medical history and weight goals to see if you medically qualify — no cost, no obligation.
A licensed physician reviews your assessment, BMI, and goals via a secure telemedicine visit.
If tirzepatide is appropriate, your physician issues your prescription and your starting dose.
Your medication ships from a licensed pharmacy to your door, with ongoing monthly clinical support included.
Eligibility is always determined by a licensed physician during your clinical evaluation. These are the general guidelines for weight management.
Take the free quiz and our care team will help you understand your options — no commitment required.
Clinical trials paired the medication with diet and activity for a reason. These habits help protect muscle, ease side effects, and support lasting results.
Aim for protein at each meal to help preserve muscle while you lose fat, and to stay satisfied on a smaller appetite.
Combine regular movement with strength training. Resistance work is especially important for maintaining lean mass.
Plenty of water and fiber-rich foods help manage common digestive side effects like constipation.
Pick a consistent weekly injection day so the medication stays at steady levels and you don't miss doses.
Ongoing check-ins and community make the journey feel less isolating and help you stay consistent.
Build habits you can keep. Lasting results come from pairing medication with sustainable lifestyle change.
Most side effects are gastrointestinal and typically mild, most common at the start or after a dose increase, and improve as your body adjusts.
Most common at the start or after dose increases. Usually mild and eases within a few weeks. Smaller meals help.
Changes in digestion are common. Staying hydrated and keeping up fiber intake helps manage symptoms.
An intended effect of the medication. Make sure you're still meeting your nutritional and protein needs.
Bloating, fullness, or mild abdominal pain — especially after eating. Typically resolves as your body adjusts.
Usually dose-related. The gradual titration schedule is designed to minimize this. Report persistent symptoms.
Mild redness or swelling at the site. Rotating injection sites helps. Resolves quickly in most cases.
Rapid weight loss can raise gallstone risk. Report severe upper-abdominal pain, fever, or jaundice promptly.
Very rare but serious. Stop the medication and contact your physician immediately if you have severe, persistent abdominal pain.
Important: Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. This is a general overview and not a complete list of side effects, warnings, or interactions. Your physician will review your full health history and explain all relevant risks during your evaluation. Read full Important Safety Information →
A few simple practices keep your medication effective and your injections comfortable. Always follow the instructions that come with your medication.
Store tirzepatide in the refrigerator and do not freeze. It can be kept at room temperature for a limited time per your product's instructions.
Inject into the abdomen, thigh, or upper arm, rotating the site each week, and inject on the same day weekly.
Take it within 4 days (96 hours) of the missed dose; if more time has passed, skip it. Don't double up — ask your provider.
Place used needles and pens in an FDA-cleared sharps container — never loose in household trash.
Use tirzepatide the same day each week, at any time of day, with or without food, to keep levels steady.
Reach your care team about severe or persistent side effects, signs of an allergic reaction, or questions about your dose.
Fast Medical Weight Loss pairs proven medication with real clinical oversight and a process built around you.
Every prescription is evaluated and issued by a licensed provider — never an automated checkout.
Nationwide telemedicine access, with visits conducted by secure video or questionnaire.
Medication ships from licensed pharmacies straight to your door in plain packaging.
Your health information is protected at every step of your care.
Clear cash-pay rates plus insurance support — no surprise fees, cancel anytime.
A care team for dosing questions, side effects, and refills throughout your journey.
All-inclusive programs — licensed-physician visits and your medication included. No membership fees, cancel anytime. Multi-month plans save you more.
The 3-month and 6-month plans are billed once and are discounted versus the monthly rate. This offer cannot be combined with other discount codes or promotions. All medication requires a licensed-physician evaluation and prescription.
Clear answers to the most common questions about tirzepatide and our telemedicine program.
Yes. Tirzepatide is FDA-approved for chronic weight management under the brand name Zepbound®, and for type 2 diabetes under the brand name Mounjaro®. Both are made by Eli Lilly.
Tirzepatide activates two hormone receptors (GIP and GLP-1); semaglutide activates one (GLP-1). In a head-to-head trial, tirzepatide produced greater average weight loss — about 20.2% versus 13.7% at 72 weeks.
FDA-approved brand-name tirzepatide is available as Zepbound® and Mounjaro®. Compounded tirzepatide is not FDA-approved and may be prescribed only in specific, patient-specific situations under current law. Your physician determines the appropriate, legal option for you.
In the 72-week SURMOUNT-1 trial, adults at the highest dose lost an average of roughly 21% of their body weight alongside diet and exercise. Individual results vary based on dose, adherence, and biology.
It's a once-weekly subcutaneous injection, taken the same day each week with or without food. The dose starts at 2.5 mg and is increased gradually, up to a maximum of 15 mg, based on your response.
Research on GLP-1 medications suggests many people regain weight after stopping, since the medication controls hunger signals. Ongoing lifestyle changes matter — your physician will help build a long-term plan.
The most common are gastrointestinal — nausea, diarrhea, constipation, and decreased appetite — usually mild and temporary. Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors.
Evaluations are conducted via secure video or an asynchronous questionnaire, depending on your state and preference. All visits are HIPAA-compliant and conducted by licensed physicians.
Take the free quiz and let a licensed physician determine whether tirzepatide is right for your health profile, goals, and budget.
Start My Free ConsultationTirzepatide is the active ingredient in Zepbound® and Mounjaro®, which are trademarks of Eli Lilly and Company; Wegovy®, Ozempic®, and Rybelsus® are registered trademarks of Novo Nordisk A/S. This page has not been reviewed or endorsed by Eli Lilly or Novo Nordisk. Tirzepatide is FDA-approved for chronic weight management under the brand name Zepbound®, and for type 2 diabetes under the brand name Mounjaro®. Brand-name tirzepatide is FDA-approved; compounded tirzepatide is not FDA-approved and, following the resolution of the tirzepatide shortage, may be prescribed only in limited, patient-specific circumstances under applicable federal and state law, which has been changing. *Weight-loss figures are from the SURMOUNT clinical program (e.g., SURMOUNT-1, ~21% average reduction at the highest dose over 72 weeks; SURMOUNT-5, 20.2% vs 13.7% for semaglutide), combined with a reduced-calorie diet and increased physical activity; individual results vary. ‡The $399/month program includes licensed-physician visits and a monthly medication supply, with no membership fees; cancel anytime. The 3-month and 6-month plans are billed once and are discounted versus the monthly rate; these offers cannot be combined with other discount codes or promotions. Pricing shown is illustrative and subject to change. Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors. This page is for informational purposes only and does not constitute medical advice. All treatment requires a licensed physician evaluation, eligibility, and a prescription; not all patients will qualify. Prescriptions require an online consultation with a healthcare provider who will determine whether a prescription is appropriate. Medication is dispensed through licensed pharmacies. ©2026 Fast Medical Weight Loss. HIPAA Compliant. All Rights Reserved.
©2026 All Rights Reserved. fastmedicalweightloss.org
